INDIANAPOLIS, Ind. - Eli Lilly and Company, a major pharmaceutical company, announced on Monday that its weight-loss drug, ...

Direct-to-consumer health startup Ro has partnered with Eli Lilly to provide more affordable ... loss drug Zepbound, streamlining access through a seamless platform. The initiative integrates ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion. Access and affordability have limited wider use of the drugs. Tirzepatide and semaglutide were ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage ... CVS said Caremark will offer Wegovy at "a more affordable price." As a pharmacy benefit manager, Caremark ...

Michael Headrick says he’s lost 18 pounds since starting Zepbound injections about a month ago, with no noticeable side effects. (Photo courtesy of Adam Seif) Michael Headrick of Indianapolis ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.